SFX by Ex Libris Inc.

Title:	Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin
Source:	Febs Letters [0014-5793] Almeida, Maria yr:2012

Basic

Full text

Full text available via Wiley Online Library Full Collection 2019

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Johnson, Steven M. "The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug." Journal of Molecular Biology 421.2-3 (2012): 185-203.
description	2.	Fujiki, Y. "Peroxisome biogenesis disorders: Molecular basis for impaired peroxisomal membrane assembly: In metabolic functions and biogenesis of peroxisomes in health and disease." Biochimica et biophysica acta. Molecular basis of disease 1822.9 (2012): 1337-1342.
description	3.	Benson, Merrill D. "Pathogenesis of transthyretin amyloidosis." Amyloid 19.1 (2012): 14-15.
description	4.	Invernizzi, G. "Protein aggregation: Mechanisms and functional consequences." International journal of biochemistry & cell biology 44.9 (2012): 1541-54.
description	5.	Ptashne, M. "Epigenetics: Core misconcept." Proceedings of the National Academy of Sciences of the United States of America 110.18 (2013): 7101-3.
description	6.	Gasperini, Robert J. "Neurodegeneration in Familal Amyloidotic Polyneuropathy." Clinical and experimental pharmacology & physiology 39.8 (2011): 680-683.
description	7.	Blasi, D. "Drug discovery targeted at transthyretin cardiac amyloidosis: rational design, synthesis, and biological activity of new transthyretin amyloid inhibitors." Amyloid 18.SUPPL. 1 (2011): 55-57.
description	8.	Connelly, S. "Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses." Current opinion in structural biology 20.1 (2010): 54-62.
description	9.	Kincaid, MD D. "The molecular biology and clinical features of amyloid neuropathy." Muscle & nerve 36.4 (2007): 411-423.
description	10.	Bachmair, A. "In vivo half-life of a protein is a function of its amino-terminal residue." Science 234.4773 (1986): 179-86.
description	11.	Benson, Merrill D. "Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment." Amyloid 17.2 (2010): 43-49.
description	12.	Tatsumi, K. "Enhanced expression of a-series gangliosides in fibroblasts of patients with peroxisome biogenesis disorders." Biochimica et biophysica acta. Molecular basis of disease 1535.3 (2001): 285-293.
description	13.	Fransen, M. "Role of peroxisomes in ROS/RNS-metabolism: Implications for human disease." Biochimica et biophysica acta. Molecular basis of disease 1822.9, Sp. Iss. SI (2012): 1363-1373.
description	14.	Waterham, Hans R. "Genetics and molecular basis of human peroxisome biogenesis disorders." Biochimica et biophysica acta 1822.9 (2012): 1430-1441.
description	15.	Yurimoto, H. "Yeast methylotrophy: Metabolism, gene regulation and peroxisome homeostasis." International Journal of Microbiology 2011.2011 (2011): 1-8.
description	16.	Almeida, N. "Transthyretin Deposition in Familial Amyloidotic Polyneuropathy." Current medicinal chemistry 19.15 (2012): 2304-2311.
description	17.	Mast, Fred D. "A Drosophila model for the Zellweger spectrum of peroxisome biogenesis disorders." Disease models & mechanisms 4.5 (2011): 659-672.
description	18.	Walsh, C M H. "Biophysical analysis of normal transthyretin: implications for fibril formation in senile systemic amyloidosis." Amyloid 8.2 (2001): 75-83.
description	19.	Taylor, Kenneth H P. "Toxic Proteins in Neurodegenerative Disease." Science 296.5575 (2002): 1991-5.
description	20.	Ho, L W W. "The molecular biology of Huntington's disease." Psychological medicine 31.1 (2000): 3-14.